Liver Enzymes as Biomarkers for Hepatotoxity of Statins in Patients with Dyslepidemia

Velickova, Nevenka and Nateva, Marina and Stojanovska, Slagana (2019) Liver Enzymes as Biomarkers for Hepatotoxity of Statins in Patients with Dyslepidemia. In: nternational Conference on Medical and Biological Engineering – CMBEBIH 2019, 16-18 May 2019, Banja Luka, Bosnia.

[thumbnail of Velickova_CMBEBIH2019-Poster.pdf]

Download (963kB) | Preview
[thumbnail of FINAL_CMBEBIH2019-Conference-Program.pdf]

Download (478kB) | Preview


Various chemical agents or pharmaceuticals as drugs administered into the body in increased concentrations for a long time may have hepatotoxic or carcinogenic effect. In human biomonitoring are used different biomarkers, which can confirm the presence of various chemical agents in the body and their effects on cells or molecules. The aim of the study is to biomonitoring of the hepatotoxic effects of statins (atorvastatin and rosuvastatin) as a chemical agents or drugs in therapy on patients with dyslipidemia, using biochemical biomarkers as liver enzymes. Material and methods: Follow-up laboratory tests (AST, ALT, GGT, ALP, cholesterol, and triglycerides) were evaluated with biochemical analyzer Cobas Integra 400 Plus, after 6 months of treatment with statins. The study included 28 subjects, aged 28–84 years (mean 63,7), 15 women and 13 men, mainly patients with confirmed dyslipidemia. Results: The observation of total serum transferases confirme that 20 of the subjects (71,42%) have a normal serum trasferases (AST and ALT) but 8 of the subjects (28,58%) (GROUP 1 and 2) have a abnormal level of serum trasferases. Subjects in GROUP 1 (5 subjects with atorvastatin therapy) have a abnormal level of serum trasferases (AST and ALT), the mean values for AST was 43.6 U/ L and for ALT 73,6 U/L. Subject in GROUP 2 (3 subjects with rosuvastatin therapy) have >10 times more of the level of AST and ALT (the mean value for AST was 580,3 U/L, and for ALT 1802,3 U/L). In the GROUPE 2 we reported older patients (with the ages after 60) with long time therapy with rosuvastatin (more than 6 months) who demonstrated significant elevation of ALT according with other chronical diseases as a cardiovascular diseases, diabetis melithus type 2 and acute pancreatitis and in alcohol abusers. Conclusions: We want to emphasized the importance of biomonitoring of liver enzimes as biomarkers which associated hepatotoxicity. Statins therapy (on patients with dyslipidemia) combined with other metabolic drugs and inhibitors, might increase the risk of liver injury. Individual differences, such as sex, age, sensitivity and immune ability, affect the degree of hepatotoxicity of various drugs (in our study statins) as a chemical agents present in the body.

Key words: statins, dyslipidemia, liver enzymes, hepatotoxity, biomonitoring

Item Type: Conference or Workshop Item (Poster)
Subjects: Medical and Health Sciences > Basic medicine
Divisions: Faculty of Medical Science
Depositing User: Nevenka Velickova
Date Deposited: 18 Jul 2019 09:27
Last Modified: 18 Jul 2019 09:27

Actions (login required)

View Item View Item